Contents

Number 1, January 1985

Papers

1 The effects of dazoxiben, an inhibitor of thromboxane synthetase, on cold-induced forearm vasoconstriction and platelet behaviour in different individuals: *A. J. Cowley, E. W. Jones, A. J. Carter, S. P. Hanley & S. Heptinstall*

9 Inhibition of food stimulated acid secretion by misoprostol, an orally active synthetic E_1 analogue prostaglandin: *J. K. Ramage, A. Denton & J. G. Williams*

13 β_1-selective and non-selective β-adrenoceptor blockade, anaerobic threshold and respiratory gas exchange during exercise: *A. A. McLeod, K. D. Knopes, D. G. Shand & R. Sanders Williams*

21 The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man: *J. N. Harvey, D. P. Worth, J. Brown & M. R. Lee*

29 Effect of angiotensin II and captopril on renal tubular function in man: *R. Düsing, J. Moritz, K. Glänzer & H. J. Kramer*

37 A comparison of the effects of intravenous propranolol and nadolol on the renal response to hypertonic saline infusion: *D. G. Waller, J. Mihindukulasuriya & D. J. Warren*

45 Calcium antagonists stimulate sperm motility in ejaculated human semen: *C. Y. Hong, B. N. Chiang, J. Ku, Y. H. Wei & J. C. Fong*

51 Interaction of propoxyphene with diazepam, alprazolam and lorazepam: *D. R. Abernethy, D. J. Greenblatt, Diane S. Morse & R. I. Shader*

59 Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons: *O. Pelkonen, E. A. Sotaniemi & J. T. Ahokas*

67 Metoclopramide reduces carbohydrate absorption in man: *A. M. Holgate & N. W. Read*

73 Cardiac effects of sodium stibogluconate: *A. Henderson & D. Jolliffe*

79 The pharmacokinetics and bioavailability of a tracer dose of [^{3}H]-mebendazole in man: *M. Dawson, P. A. Braithwaite, M. S. Roberts & T. R. Watson*

Short reports

87 The effect of dose form on the bioavailability of mebendazole in man: *M. Dawson & T. R. Watson*

91 Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-*N*-oxide following i.v. and oral administration in healthy volunteers: *A. McBurney, P. R. Farrow, S. Ainsworth & J. W. Ward*

95 Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788: *U. Klotz, Th. Duka, R. Dorow & A. Doenicke*

99 Lack of effect of amoxicillin on theophylline pharmacokinetics: *J. H. G. Jonkman, W. J. V. van der Boon, R. Schoenmaker, A. Holtkamp & J. Hempenius*

102 Thrombocytopenia and leucopenia with mianserin-dependent antibodies: *B. H. Ch. Stricker, J. N. M. Barendregt & F. H. J. Claas*

105 Strength of the human mixed lymphocyte reaction (MLR) and its suppression by azathioprine or 6-mercaptopurine: *S. A. Al-Safi & J. L. Maddocks*

108 Lack of inhibition of purine nucleoside phosphorylase and adenosine deaminase in patients treated with azathioprine: *J. L. Maddocks & S. A. Al-Safi*

Letters to the Editors

113 A double-blind placebo controlled study to examine effects of sucralfate on paracetamol absorption: *F. Kamali, J. R. Fry, H. L. Smart & G. D. Bell*

114 Indirect blood pressure measurement during intravenous isoprenaline infusions: *J. M. O. Arnold & D. G. McDevitt*

115 Wellcome Trust support for clinical pharmacology in the UK: *P. O. Williams*

Proceedings

119 Proceedings of the British Pharmacological Society (University of Dundee, 11–14 September 1984)

Number 2, February 1985

Papers

155 Is the clinical trial evidence about new drugs statistically adequate?: *J. M. Bland, D. R. Jones, S. Bennett, D. G. Cook, A. P. Haines & Alison J. MacFarlane*

161 Protein binding and CSF penetration of phenytoin following acute oral dosing in man: *M. J. Brodie, S. E. Muir, E. Agnew, G. J. A. MacPhee, G. Volo, E. Teasdale & P. MacPherson*

169 A class experiment in clinical pharmacology using β-adrenoceptor antagonist drugs: *C. R. Kumana & C. W. Ogle*

177 The effect of a week's β-adrenoceptor antagonism on daytime heart-rates, subjective responses to exercise and physical activity in normal subjects: *J. M. Patrick, H. J. Wharrad, C. G. Wilson & A. T. Birmingham*

187 Ethnic differences in human lymphocytic cyclic

AMP production after isoprenaline stimulation and propranolol blockade: *C. P. Venter, S. Daya, P. H. Joubert & W. J. Strydom*
191 Renal excretion of intravenously infused amoxycillin and ampicillin: *J. Sjövall, D. Westerlund & G. Alván*
203 Pharmacokinetics of metronidazole in patients with varying degrees of renal failure: *G. W. Houghton, M. J. Dennis & R. Gabriel*
211 Pharmacokinetics of ornidazole in patients with renal insufficiency: influence of haemodialysis and peritoneal dialysis: *H. Merdjan, A. Baumelou, B. Diquet, O. Chick & E. Singlas*
219 Effects of ranitidine on the disposition of metoprolol: *J. G. Kelly, S. A. M. Salem, C. D. Kinney, R. G. Shanks & D. G. McDevitt*
225 Comparison of the urinary metabolite profile of caffeine in young and elderly males: *J. Blanchard, S. J. A. Sawers, J. H. G. Jonkman & D. Dan-Shya Tang-Liu*
233 Pharmacokinetics of aztreonam in elderly male volunteers: *W. A. Creasey, T. B. Platt, May Frantz & A. A. Sugerman*
239 Nicotine pharmacokinetics and its application to intake from smoking: *C. Feyerabend, R. M. J. Ings & M. A. H. Russell*
249 Lack of effect of tenoxicam on glibornuride kinetics and response: *K. Stoeckel, V. Trueb, U. C. Dubach, R. C. Heintz, V. Ascalone, I. Forgo & U. Hennes*

Short reports
255 Side-effects of β-adrenoceptor blocking drugs assessed by visual analogue scales: *R. V. Lewis, P. R. Jackson & L. E. Ramsay*
258 Treatment with β-adrenoceptor blockers reduces plasma melatonin concentration: *P. J. Cowen, J. S. Bevan, B. Gosden & S. A. Elliott*
261 The effects of age and smoking on the plasma protein binding of lignocaine and diazepam: *D. Davis, S. H. Grossman, Barbara B. Kitchell, D. G. Shand & P. A. Routledge*
266 Indoramin–prolongation of repolarization time, a mechanism of bradycardia in man?: *D. W. G. Harron, D. P. Nicholls & R. G. Shanks*
272 Cimetidine's effect on dermal H_1-receptor antagonist tolerance: *G. M. Fairris & N. Fairris*
275 Red wine contains a potent inhibitor of phenolsulphotransferase: *Julia T. Littlewood, Vivette Glover & Merton Sandler*

Number 3, March 1985

Papers
279 Drug metabolising activity of freshly isolated human hepatocytes: *Lisa B. G. Tee, T. Seddon, A. R. Boobis & D. S. Davies*
295 Comparison of the effects of binodaline and amitriptyline on peripheral autonomic functions in healthy volunteers: *J. Longmore, E. Szabadi & C. M. Bradshaw*
301 The effect of secoverine hydrochloride on stimulated sigmoid motility: a double-blind, placebo controlled cross-over study in irritable bowel syndrome: *M. Ehsanullah, D. A. H. Lee, T. Williams, P. Pollard & B. Gazzard*
307 The evaluation of domperidone and metoclopramide as antiemetics in day care abortion patients: *C. S. Waldmann, Chandy Verghese, S. M. Short, D. R. Goldhill & S. J. W. Evans*
311 The plasma noradrenaline and growth hormone response to α-methyldopa and clonidine in hypertensive subjects: *A. D. Struthers, M. J. Brown, E. F. Adams & C. T. Doll*
319 Human pharmacokinetic and pharmacodynamic studies on Ro 31-1118, a new β-adrenoceptor antagonist: *P. C. O'Connor, J. M. O. Arnold, A. N. Brown, R. J. Francis, M. B. Finch, D. B. Galloway, D. W. G. Harron, D. G. McDevitt & R. G. Shanks*
329 Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics: *R. V. Lewis, M. S. Lennard, P. R. Jackson, G. T. Tucker, L. E. Ramsay & H. F. Woods*
335 The effect of dietary supplementation with linoleic and gammalinolenic acids on the pressor response to angiotensin II—a possible role in pregnancy-induced hypertension: *P. M. S. O'Brien, R. Morrison & F. Broughton Pipkin*
343 Comparative clinical efficacy of bepridil, propranolol and placebo in patients with chronic stable angina: *A. P. Rae, J. M. Beattie, T. D. V. Lawrie & I. Hutton*
353 Effects of repeated doses of enalapril on renal function in man: *W. R. McNabb, F. H. Noormohamed, B. A. Brooks, A. E. Till & A. F. Lant*
363 Influence of advanced age on the disposition of acetazolamide: *D. J. Chapron, K. R. Sweeney, P. U. Feig & P. A. Kramer*
373 Oxaprozin pharmacokinetics in the elderly: *D. J. Greenblatt, Rita Matlis, J. M. Scavone, G. T. Blyden, J. S. Harmatz & R. I. Shader*
379 Pharmacokinetic interaction of acetylsalicylic acid and dipyridamole: *Eva Nitelius, A. Melander & Elisabeth Wåhlin-Boll*
385 Verapamil disposition—effects of sulphinpyrazone and cimetidine: *L. M. H. Wing, J. O. Miners & Karen J. Lillywhite*

Short reports
393 The influence of captopril, the nitrates and propranolol on apparent liver blood flow: *A. N. Shepherd, P. C. Hayes, Meron Jacyna, Lindsay Morrison & I. A. D. Bouchier*
398 Pharmacokinetic interaction of propoxyphene with ethanol: *E. M. Sellers, Carolyn A. Hamilton, H. L. Kaplan, Naeema C. Degani & R. L. Foltz*

Letter to the Editors
403 Influence of posture on plasma nitroglycerin: *S. H. Curry & H.-R. Kwon*

Number 4, April 1985

Papers

405 Comparative effects of adimolol, labetalol and propranolol on heart rate and blood pressure in man: *J. G. Riddell, D. W. G. Harron & R. G. Shanks*

411 Dynamics of β-adrenoceptor blockade with cetamolol: *J. Coelho, K. Schnelle, L. Joubert, D. Ventura & J. Mullane*

417 The effects of propranolol and digoxin on the acute vascular responses to frusemide in normal man: *G. D. Johnston, P. C. O'Connor, D. P. Nicholls, W. J. Leahey & M. B. Finch*

423 The natriuresis following oral administration of the calcium antagonists—nifedipine and nitrendipine: *M. D. Ene, P. J. Williamson, C. J. C. Roberts & G. Waddell*

429 Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure: *B. MacMahon, M. Bakshi, P. Branagan, J. G. Kelly & M. J. Walsh*

435 A possible explanation for the absence of anti-anginal properties of transdermal nitroglycerin units: an echocardiographic study: *E. D. Bennett & A. L. Davis*

441 The effect of domperidone on oesophageal emptying in diabetic autonomic neuropathy: *G. J. Maddern, M. Horowitz & G. G. Jamieson*

445 A comparison of the effects of lorazepam with those of propranolol on experimentally-induced anxiety and performance: *Sandra E. File & R. G. Lister*

453 Increased platelet membrane [^{3}H]-LSD binding in patients on chronic neuroleptic treatment: *M. Schächter, D. P. Geaney, D. G. Grahame-Smith, P. J. Cowen & J. M. Elliott*

459 Lung function and plasma levels of thromboxane β_2, 6-keto-prostaglandin $F_{1\alpha}$ and β-thromboglobulin in antigen-induced asthma before and after indomethacin pretreatment: *Enid G. Shephard, L. Malan, C. M. Macfarlane, W. Mouton & J. R. Joubert*

471 The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve: *P. Fitzharris, A. E. M. McLean, R. G. Sparks, B. C. Weatherley, R. D. White & R. Wootton*

483 Genetic polymorphism of mephenytoin *p*(4′)-hydroxylation: difference between Orientals and Caucasians: *M. Jurima, T. Inaba, D. Kadar & W. Kalow*

489 Pharmacokinetics of potassium chloride in wax-based and syrup formulations: *J. M. Toner & L. E. Ramsay*

495 Oral morphine in cancer patients: *in vivo* kinetics and *in vitro* hepatic glucuronidation: *Juliette Säwe, L. Kager, J.-O. Svensson Eng & A. Rane*

503 Tinidazole milk excretion and pharmacokinetics in lactating women: *G. R. Evaldson, S. Lindgren, C.-E. Nord & A. T. Rane*

Short reports

509 Aztreonam in human serum and breast milk: *P. M. Fleiss, G. A. Richwald, J. Gordon, M. Stern, M. Frantz & R. G. Devlin*

512 An investigation of the cause of accumulation of verapamil during regular dosing in patients: *Janice B. Schwartz, D. R. Abernethy, A. A. Taylor & J. R. Mitchell*

517 Plasma concentrations of melatonin in man following oral absorption of different preparations: *M. Aldhous, C. Franey, J. Wright & J. Arendt*

Letters to the Editors

523 Indomethacin does not attenuate the ocular hypotensive effect of timolol: *Q. A. Mekki, S. M. L. Abrams, A. D. Petounis & P. Turner*

524 A comparison of standard and sustained release clonidine with respect to plasma concentration and blood pressure changes: *J. L. Shaffer, B. J. Pleuvry, D. S. Davies & S. Murray*

526 The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration: *J. L. Shaffer & J. B. Houston*

528 Possible interaction between aminophylline and ascorbic acid: *M. Furlanut, G. Montanari & F. Rusca*

529 Protein binding of theophylline: *D. C. Buss, P. Ebden, S. Baker & P. A. Routledge*

Proceedings

533 Proceedings of the British Pharmacological Society (University of London, 17–19 December 1984)

Number 5, May 1985

Papers

593 Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man: *N. D. S. Bax, R. W. Jones, M. S. Lennard, G. T. Tucker & H. F. Woods*

597 The impairment of lignocaine clearance by propranolol—major contribution from enzyme inhibition: *N. D. S. Bax, G. T. Tucker, M. S. Lennard & H. F. Woods*

605 Effective dose range of enalapril in mild to moderate essential hypertension: *R. Bergstrand, H. Herlitz, S. Johansson, G. Berglund, A. Vedin, C. Wilhelmsson, H. J. Gomez, V. J. Cirillo & J. A. Bolognese*

613 Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure: *P. Ghirhardi, B. Brusoni, M. Mangiavacchi, L. Bianco, J. Col, M. Metra & L. Dei Cas*

619 Effects of the β_2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced β-adrenoceptor responses in man:

J. M. O. Arnold, P. C. O'Connor, J. G. Riddell, D. W. G. Harron, R. G. Shanks & D. G. McDevitt

631 Inhibition of histamine release from dispersed human lung and tonsillar mast cells by nicardipine and nifedipine: *Y.-Y. Kim, S. T. Holgate & M. K. Church*

639 Comparison of the effects of chronic administration of ciclazindol and desipramine on pupillary responses to tyramine, methoxamine and pilocarpine in healthy volunteers: *F. A. Kerr & E. Szabadi*

649 Pharmacokinetics and pharmacodynamics following single and repeated nightly administrations of loprazolam, a new benzodiazepine hypnotic: *G. T. McInnes, E. A. Bunting, R. M. J. Ings, J. Robinson & S. I. Ankier*

657 Comparative pharmacodynamics and clinical pharmacokinetics of phenoxymethylpenicillin and pheneticillin: *D. Overbosch, H. Mattie & R. van Furth*

669 Stereoselective disposition of ibuprofen enantiomers in man: *E. J. D. Lee, K. Williams, R. Day, G. Graham & D. Champion*

675 The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites: *P. C. Ho, E. J. Triggs, D. W. A. Bourne & V. J. Heazlewood*

685 Specific antagonism of adenosine-induced bronchoconstriction in asthma by oral theophylline: *J. S. Mann & S. T. Holgate*

Short reports

693 Audit of a monitoring service for free phenytoin: *G. M. Peterson, S. McLean, R. J. von Witt & K. S. Millingen*

698 Antipyrine clearance in children from single saliva samples: *S. Loft, O. Hæxholdt & M. Døssing*

701 Enalapril (MK421) activation in man: importance of liver status: *I. Larmour, B. Jackson, R. Cubela & C. I. Johnston*

705 A comparison of the effect of paroxetine and amitriptyline on the tyramine pressor response test: *S. M. Hassan, G. Wainscott & P. Turner*

707 Posture and theophylline kinetics: *J. B. Warren, F. Cuss & P. J. Barnes*

Letters to the Editors

711 Ranitidine does not potentiate mediator release from human lung *in vitro*: *J. M. Hughes, J. P. Seale & D. M. Temple*

712 Influence of chronic dosing on theophylline clearance: *S. Vožeh & F. Follath*

713 Influence of chronic dosing on theophylline clearance: *D. J. Morgan, K. Raymond & A. J. McLean*

Number 6, June 1985

Papers

715 Differential effect of platelet inhibitors in normal and in hypercholesterolaemic subjects: *M. Aviram, G. Winterstein & J. G. Brook*

721 Attempts to phenotype human liver samples *in vitro* for debrisoquine 4-hydroxylase activity: *A. R. Boobis, C. E. Hampden, S. Murray, P. Beaune & D. S. Davies*

731 Effects of verapamil on calcium-induced rigidity and on filterability of red blood cells from healthy volunteers and patients with progressive systemic sclerosis: *S. O. Sowemimo-Coker, I. B. Kovacs, J. D. T. Kirby & P. Turner*

739 Involvement of calcium in the caffeine stimulation of human sperm motility: *C. Y. Hong, B. N. Chiang, P. Wu, Y. H. Wei & J. C. Fong*

745 Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size: *G. W. Mihaly, S. A. Ward, G. Edwards, D. D. Nicholl, M. L'E. Orme & A. M. Breckenridge*

751 Pharmacokinetics of primaquine in man. II. Comparison of acute *vs* chronic dosage on Thai subjects: *S. A. Ward, G. W. Mihaly, G. Edwards, S. Looareesuwan, R. E. Phillips, P. Chanthavanich, D. A. Warrell, M. L'E. Orme & A. M. Breckenridge*

757 The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease: *S. M. Bryson, E. M. McGovern, A. W. Kelman, K. White, G. J. Addis & B. Whiting*

767 Effect of charcoal-drug ratio on antidotal efficacy of oral activated charcoal in man: *K. T. Olkkola*

775 Pharmacological experiments in healthy volunteers with bopindolol, a long-acting β-adrenoceptor blocking drug with partial agonist activity: *W. H. Aellig*

783 The effect of acute β-adrenoceptor blockade on examination performance: *P. J. T. Drew, J. N. Barnes & S. J. W. Evans*

787 A comparative study of a new selective β_2-adrenoceptor agonist, procaterol, and salbutamol in asthma: *M. J. Crowe, H. E. Counihan & K. O'Malley*

793 Chlorpromazine—a specific effect on breathlessness? *P. A. O'Neill, P. B. Morton & R. D. Stark*

799 Plasma melatonin during desmethylimipramine treatment: evidence for changes in noradrenergic transmission: *P. J. Cowen, A. R. Green, D. G. Grahame-Smith & L. E. Braddock*

807 Central effects during the continuous osmotic infusion of a benzodiazepine (triazolam): *D. D. Breimer, R. Jochemsen, H. A. C. Kamphuisen, A. N. Nicholson, M. B. Spencer & B. M. Stone*

817 Hyper-responsiveness of eccrine sweat glands to carbachol in anxiety neurosis: comparison of male and female patients: *J. M. Buceta, C. M. Bradshaw & E. Szabadi*

Short reports

823 The *ex vivo* plasma protein binding of theophylline in renal disease: *D. Leopold, D. Webb, D. C. Buss, R. A. Fifield, A. P. Smith & P. A. Routledge*

826 Measuring side-effects of β-adrenoceptor antagonists: a comparison of two methods: *R. V. Lewis, P. R. Jackson, & L. E. Ramsay*

829 A placebo controlled comparison of the effects of

pirenzipine and amitriptyline on the tyramine pressor test in healthy volunteers: *M. R. Wilkins, R. D. Wynne & M. J. Kendall*
832 Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients—relationship to the debrisoquine hydroxylation metabolic ratio: *C. Nordin, B. Siwers, J. Benitez & L. Bertilsson*
836 The effect of activated charcoal and hyoscine butylbromide alone and in combination on the absorption of mefanamic acid: *N. El-Bahie, E. M. Allen, J. Williams & P. A. Routledge*
839 Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics: *P. D. Kroboth, R. B. Smith, M. R. Silver, R. Rault, M. I. Sorkin, J. B. Puschett & R. P. Juhl*
843 Chronopharmacokinetics of paracetamol in normal subjects: *J. Malan, J. Moncrieff & E. Bosch*
846 The influence of cimetidine and ranitidine on the plasma lipid pattern: *V. Terruzzi, G. Minoli, G. Tadeo, M. Nespoli & A. Rossini*
849 Fenfluramine delays gastric emptying of solid food: *M. Horowitz, P. J. Collins, V. Tuckwell, J. Vernon-Roberts & D. J. C. Shearman*
852 The cardiovascular effects of regular and decaffeinated coffee: *P. Smits, Th. Thien & A. Van'T Laar*

Letters to the Editors
855 Drug metabolite kinetics: noncompartmental analysis: *M. Weiss*
856 Excretion of disopyramide in human breast milk: *D. MacKintosh & N. Buchanan*
857 Mexiletine clearance during peritoneal dialysis: *D. R. P. Guay, R. C. Meatherall, I. Ferguson, H. Smith & B. Light*
858 Effect of raniditine on procainamide disposition: *B. K. Martin*
860 Correction equation for ECG time intervals: *S. J. W. Evans*
861 Correction equation for ECG time intervals: a reply: *A. W. Kelman, B. Whiting & D. J. Sumner*
862 Correction equation for QT interval: *D. H. Staniforth*

Indexes
863 Author and subject indexes to Volume 19

Supplement 1, 1985

Proceedings of the symposium on New Approaches to Diagnosis and Treatment of Affective Disorders Vienna, March, 1984

3S **Preface**
5S Introduction: *A. Clare*

Diagnosis
9S Neurotic illness: conserving a threatened concept: *A. Sims*
17S Rating scales for depression and anxiety: a current perspective: *R. P. Snaith & C. M. Taylor*
21S Computers working for medicine: *Gillian Richmond*

Treatment
29S Treatment of affective disorders: *M. H. Lader*
31S The use of benzodiazepines in depression: *D. A. W. Johnson*
37S A double-blind comparison of alprazolam, diazepam and placebo in the treatment of anxious out-patients: *K. Davison, R. G. Farquharson, M. C. Khan & A. Majid*
45S Antidepressant properties of the triazolobenzodiazpines, alprazolam and adinazolam: studies on the olfactory bulbectomized rat model of depression: *W. T. O'Connor, Bernadette Earley & B. E. Leonard*
57S Brief review of published alprazolam clinical studies: *R. N. Straw*
61S **Discussion**

Supplement 2, 1985

Oros drug delivery systems for the β-adrenoceptor antagonists: oxprenolol and metoprolol

63S **Preface**

Controlled-release dosage forms
65S The role of clinical pharmacology in the development and evaluation of oral controlled-release dosage forms: *M. J. Kendall & V. A. John*
69S Osmotic delivery systems for the β-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration: *F. Theeuwes, D. R. Swanson, G. Guittard, A. Ayer & S. Khanna*

Basic absorption studies
77S The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation: *J. Hirtz*
85S Gastric, intestinal, and colonic absorption of metoprolol in the rat: *J. Doménech, M. Alba, J. M. Morera, R. Obach & J. M. Plá Delfina*
91S Evaluation of oxprenolol and metoprolol Oros systems in the dog: comparison of *in vivo* and *in vitro* drug release, and of drug absorption from duodenal and colonic infusion sites: *J. W. Fara, R. E. Myrback & D. R. Swanson*

97S Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum: *G. Jobin, A. Cortot, J. Godbillon, M. Duval, J. P. Schoeller, J. Hirtz & J. J. Bernier*

107S Investigation of drug absorption from the gastrointestinal tract of man. II. Metoprolol in the jejenum and ileum: *N. Vidon, D. Evard, J. Godbillon, M. Rongier, M. Duval, J. P. Schoeller, J. J. Bernier & J. Hirtz*

113S Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon: *J. Godbillon, D. Evard, N. Vidorn, M. Duval, J. P. Schoeller, J. J. Bernier & J. Hirtz*

119S Investigation of drug absorption from the gastrointestinal tract of man. IV. Influence of food and digestive secretions on the jejunal absorption of metoprolol: *D. Evard, N. Vidon, J. Godbillon, M. Bovet, M. Duval, J. P. Schoeller, J. J. Bernier & J. Hirtz*

127S Investigation of drug absorption from the gastrointestinal tract of man. V. Effect of the β-adrenoceptor antagonist, metoprolol, on postprandial gastric function: *G. Jobin, A. Cortot, E. Danquechin-Dorval, J. Godbillon, J. P. Schoeller, J. J. Bernier & J. Hirtz*

137S Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing: *K.-H. Antonin, P. Bieck, M. Scheurlen, M. Jedrychowski & H. Malchow*

Evaluation techniques

143S Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis: *A. Racine-Poon & J. Moppert*

151S *In vitro* and *in vivo* deconvolution assessment of drug release kinetics from oxprenolol Oros preparations: *F. Langenbucher & J. Mysicka*

Oxprenolol Oros studies

163S Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of *in vivo* and *in vitro* drug release: *I. D. Bradbrook, V. A. John, P. J. Morrison, H. J. Rogers & R. G. Spector*

171S Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms in healthy volunteers: *P. N. Bennett, J. Bennett, I. Bradbrook, J. Francis, V. A. John, H. Rogers, P. Turner & S. J. Warrington*

177S A multiple-dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers: *K. L. Woods, D. B. Jack, M. J. Kendall, Alison Halsey, M. Louise M. O'Donnell, S. J. Warrington & V. A. John*

185S Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form: *D. B. Jack, M. J. Kendall, S. J. Laugher & S. R. Smith*

191S Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations: *V. A. John & S. E. Smith*

197S Pre-dosing plasma concentrations and β-adrenoceptor blocking effects during repeated once-daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers: *J. Moppert, P. H. Degen & A. Racine-Poon*

203S Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report: *V. A. John, P. A. Shotton, J. Moppert & W. Theobald*

207S Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily: *F. B. Müller, L. F. Allsopp, G. L. Cooper, P. Bolli, P. Frei, L. Glaus, R. Ritz & F. R. Bühler*

Metoprolol Oros studies

213S Osmotically controlled-delivery of metoprolol in man: *in vivo* performance of Oros systems with different durations of drug release: *J. Godbillon, A. Gerardin, J. Richard, D. Leroy & J. Moppert*

219S Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 Oros administration: *S. J. Warrington, S. P. Barclay, V. A. John, P. A. Shotton, H. M. Wardle & W. Good*

225S Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates: *S. J. Warrington, S. Barclay, V. A. John, P. A. Shotton & W. Good*

231S Oros controlled-release formulations for metoprolol: an approach to the development of a system for once-daily administration: *W. Good, L. J. Lesson, S. L. Zak, W. E. Wagner, J. B. Meeker & J. D. Arnold*

239S A multiple-dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers: *S. L. Grainger, V. A. John, P. A. Shotton & S. E. Smith*

245S Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man: *J. B. Lecaillon, P. Massias, J. P. Schoeller & F. Abadie*